GEO Logo
   NCBI > GEO > Accession DisplayHelp Not logged in | LoginHelp
GEO help: Mouse over screen elements for information.
Series GSE78011 Query DataSets for GSE78011
Status Public on Feb 01, 2017
Title RNA-Seq Analysis of Anacardic Acid Treated MCF7 and MDA-MB-231 Breast Cancer Cell Lines
Organism Homo sapiens
Experiment type Expression profiling by high throughput sequencing
Summary Anacardic acid (AnAc) is a mixture of 6-alkylbenzoic acid congeners that are produced in a number of plants. Previously, we showed a specific congener AnAc 24:1n5 acts as a nuclear receptor alternate site modulator (NRAM) to inhibit breast cancer cells in an estrogen receptor (ER)-dependent manner by interfering with ER-DNA binding. AnAc 24:1n5 also inhibited the growth of a triple negative breast cancer (TNBC) cell line, through an undefined mechanism. Additional work from our labs indicated AnAc 24:1n5 inhibits prostaglandin synthase and that inhibition is more specific to COX-2. Reports from other investigators indicate AnAc has a number of interesting potential pharmacological targets. We previously used qRT-PCR to investigate expression changes in endogenous estrogen-regulated genes, i.e., TFF1, CCND1, and CTSD in breast cancer cell lines. However, since AnAc has the capacity of effect multiple molecular targets and since we detected an ER-independent inhibition of breast cancer cell proliferation, we suspect additional unknown molecular targets are affected in breast cancer cells. Identification of such targets using RNA-seq would be quite beneficial in targeting TNBC which primarily affects premenopausal women with a predominance in women of African and Latina ancestry. The goal of this portion of the project is to use next-generation RNA-SEQ to identify alterations in molecular target sequence levels in ER-positive and -negative breast cancer cell lines treated with AnAc.
Overall design There are two breast cancer cell lines used in this study, including MCF-7 (invasive breast ductal carcinoma; estrogen receptor positive (ER+); progesterone receptor positive (PR+); human epidermal growth factor 2 negative (HER2-)) and MDA-MB-231 (breast adenocarcinoma; triple negative – ER-; PR-; HER2-). Each of these cell lines was treated with anacardic acid (AnActrt) with three replicates each, resulting in a total of 12 RNA samples. One MDA-MB-231 control sample and one MDA-MB-231 AnActrt treated sample were removed after QA/QC determined they were likely contaminated samples.
Contributor(s) Klinge CM, Schultz DJ, Rouchka EC, Radde BN, Li X
Citation(s) 28886127
Submission date Feb 17, 2016
Last update date Oct 11, 2019
Contact name Eric Christian Rouchka
Organization name University of Louisville
Department Biochemistry and Molecular Genetics
Lab KY INBRE Bioinformatics Core
Street address 522 East Gray Street
City Louisville
State/province Kentucky
ZIP/Postal code 40292
Country USA
Platforms (1)
GPL18573 Illumina NextSeq 500 (Homo sapiens)
Samples (10)
GSM2064538 MCF-7 cell line control replicate 1
GSM2064539 MCF-7 cell line control replicate 2
GSM2064540 MCF-7 cell line control replicate 3
BioProject PRJNA312354
SRA SRP070442

Download family Format
SOFT formatted family file(s) SOFTHelp
MINiML formatted family file(s) MINiMLHelp
Series Matrix File(s) TXTHelp

Supplementary file Size Download File type/resource
GSE78011_geneMatrix_ENSG.txt.gz 1.1 Mb (ftp)(http) TXT
SRA Run SelectorHelp
Raw data are available in SRA
Processed data are available on Series record

| NLM | NIH | GEO Help | Disclaimer | Accessibility |
NCBI Home NCBI Search NCBI SiteMap